Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc. - Common Stock (NQ: VTRS )

11.20 +0.06 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viatris Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870. 
Via Benzinga
Why Viatris Stock Is Jumping Today
Investors are applauding a key step in Viatris' plans to return to growth. 
Via The Motley Fool
Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge
Via Benzinga
Why Viatris Shares Are Soaring Higher
Viatris Inc (NASDAQ: VTRS) shares are trading higher by 16.80% to $11.33 Monday morning after the company announced it will acquire Oyster Point Pharma. What Happened? 
Via Benzinga
Viatris' Mylan Recalls One Lot Of Octreotide Acetate Injection Due To Glass Particulates
Via Benzinga
Viatris: Q2 Earnings Insights
  Viatris (NASDAQ:VTRS) reported its Q2 earnings results on Monday, August 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
IAA Stock Moves as Ritchie Bros Acquires Company in $7.3 Billion Deal
IAA (IAA) stock is moving on Monday thanks to a massive acquisition $7.3 billion deal with Ritchie Bros Auctioneers (RBA). 
Via InvestorPlace
Viatris (VTRS) Stock Pops 17% on Acquisition News
One press release with numerous positive catalysts is prompting some VTRS stock traders to load up on the shares today. 
Via InvestorPlace
What Does Sunshine Biopharma's Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market?
The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them. 
Via Benzinga
Cramer On This Stock Up 138% Year-To-Date: 'Santa Can't Afford That Coal, It's Going Up Too Much'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Cano Health Inc (NYSE: CANO). 
Via Benzinga
Recap: Viatris Q3 Earnings
Viatris (NASDAQ:VTRS) reported its Q3 earnings results on Monday, November 7, 2022 at 06:50 AM. Here's what investors need to know about the announcement. Earnings Viatris beat estimated earnings by... 
Via Benzinga
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
How To Attend Viatris Q3 2022 Earnings Conference Call
Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on November 7, 2022, to discuss Q3 2022 earnings results. How to Attend Viatris (VTRS) Conference Call Follow this link to access the... 
Via Benzinga
3 Feel-Good Ways to Lose Lots of Money in the Bear Market
All three are liable to happen when you lose your focus on investing for the long term. 
Via The Motley Fool
Recent Stock Purchase Update For October 2022
As you may know by now, I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. Let's take a look at what I've added to my portfolio... 
Via Talk Markets
3 Healthcare Stocks That Are Too Cheap to Ignore
They all offer attractive dividends, too. 
Via The Motley Fool
3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later
Procrastination could be problematic with these three bargain stocks. 
Via The Motley Fool
Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug
The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya. 
Via Benzinga
US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
Merck Stock Surges After Winning Patent Battle Vs. Viatris Over Two Key Drugs
The decision affects two of Merck's best-selling drugs. 
Via Investor's Business Daily
Recent Stock Purchase September 2022
I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. 
Via Talk Markets
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 1076 companies hit new 52-week lows. 
Via Benzinga
7 Screaming Buy Stock Picks to Beat the September Market Slump
Savvy investors can use these stock picks to beat the market and take advantage of market weakness and panic selling. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 507 stocks hit new 52-week lows. 
Via Benzinga
September 2022 Stock Considerations
Let’s take a look at my September stock considerations which are similar to recent considerations from one to four months ago. 
Via Talk Markets
This Company Reports Its Consumer Therapeutics Could Be A Game Changer For People With Skin Problems
From allergies and insect bites to sunburns and irritations, the human skin can succumb to several conditions, including acne, psoriasis, blisters, hives, actinic keratosis, rosacea, and carbuncle. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 429 stocks made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 529 companies set new 52-week lows. 
Via Benzinga
Earnings Scheduled For August 8, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.